AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis

RecruitingNAAges 0 Days - anyAllPontificia Universidad Catolica de Chile
💬

In plain words

What the trial is, and whether it could suit you

Atopic dermatitis (AD), also known as eczema, is a common chronic inflammatory skin disease that usually begins in infancy and causes significant itching, discomfort, and sleep disturbance. It affects up to one in five children worldwide and represents a growing public-health problem. Research has shown that genetic and environmental factors contribute to its development, especially those related to skin-barrier integrity and the skin microbiome during early life. Preventing AD before it starts-known as primary prevention-has become an important goal. Vernix caseosa is a naturally occurring, white, creamy substance that covers the skin of newborns at birth. It forms during the last trimester of pregnancy and plays a key role in protecting and hydrating the baby's skin before and after birth. Vernix contains water, lipids, and proteins with antimicrobial and anti-inflammatory properties.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * pregnant mother aged 18 and older, who is able to provide informed consent for participation * delivery of a healthy, singleton newborn (vaginal or cesarean) at one of the study sites. * parents are able and willing to comply with the study schedule and procedures Exclusion Criteria: * birthweight \<2000 g * prematurity younger than 34 weeks of gestation * multiple gestation / multiple births * maternal HIV-positivity * clinical and/or laboratory diagnosis of chorioamnionitis. * need for neonatal hospitalization or presence of an acute illness (e.g., neonatal respiratory distress syndrome) within the first 24 hours of life. * severe and generalized congenital skin disorder (e.g., congenital ichthyosis).
💊

What it tests

  • Retention of Vernix Caseosa After Birth
  • Removal of Vernix Caseosa After Birth
📍

Where

2 sites
Clínica San Carlos de Apoquindo
Las Condes, Chile
Hospital Clínico Universidad Católica
Santiago, Chile
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy